Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs for treatment-resistant cancers. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.
Follow-Up Questions
Quelle est la performance du prix de l'action SCPS ?
Le prix actuel de SCPS est de $0.0004, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Scopus Biopharma Inc ?
Scopus Biopharma Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Scopus Biopharma Inc ?
La capitalisation boursière actuelle de Scopus Biopharma Inc est de $16.8K
Est-ce que Scopus Biopharma Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Scopus Biopharma Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte
